Innovent Biologics, Inc. (HKG: 1801)

Hong Kong · Delayed Price · Currency is HKD

35.20

-0.80 (-2.22%)

Dec 20, 2024, 4:08 PM HKT

Innovent Biologics Employees

Innovent Biologics had 4,872 employees as of December 31, 2023. The number of employees decreased by 422 or -7.97% compared to the previous year.

Employees

4,872

Change (1Y)

-422

Growth (1Y)

-7.97%

Revenue / Employee

1.52M HKD

Profits / Employee

-261.61K HKD

Market Cap

57.65B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	4,872	-422	-7.97%
Dec 31, 2022	5,294	-274	-4.92%
Dec 31, 2021	5,568	2,289	69.81%
Dec 31, 2020	3,279	1,297	65.44%
Dec 31, 2019	1,982	1,023	106.67%
Dec 31, 2018	Pro	Pro	Pro

Innovent Biologics News

6 days ago - Innovent Biologics Inc (IVBIY) and Eli Lilly Expand Collaboration for JaypircaÂ® in China - GuruFocus
13 days ago - Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024 - PRNewsWire
18 days ago - Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer - PRNewsWire
23 days ago - Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List - PRNewsWire
27 days ago - Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024 - PRNewsWire
4 weeks ago - Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial Progress - GlobeNewsWire
6 weeks ago - Innovent Biologics (1801) Terminates Share Subscription Deal with Lostrancos - GuruFocus
7 weeks ago - Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics - PRNewsWire